Kornimate/medical-research-clean huggingface dataset:
topical use of 20% beta caryophyllene alone and in combination with 0.025% capsaicin for pain caused by osteoarthritis of the knee

Conditions: Pain

Summary: this study consists of a randomized, double-blind, placebo-controlled crossover trial with open label extension evaluating a topical natural health cream containing ß-caryophyllene alone and in combination with 0.025% capsicum oleoresin against placebo. at the end of the randomized controlled phase of the trial all participants will be given open-label combination cream to be administered over the subsequent 3 weeks. primary endpoint: evaluation of improvement in pain interference as measured by the bpi in individuals who are experiencing pain due to osteoarthritis of the knee. secondary endpoints: secondary endpoints are: confirmation of safety of the topical cream when used daily over 10 weeks. further evaluation will include overall patient satisfaction with the products tested.


Eligibility criteria:
inclusion criteria: * osteoarthritis of the knee according to american college of rheumatology criteria: knee pain with 3 of the following: * age \>50 years * stiffness less than 30 min * crepitus, * bony tenderness, * bony enlargement, * no palpable warmth * moderate to severe pain, as defined by an average 7-day pain score of greater than 4.0 on an 11-point numerical rating scale for pain intensity (nrs-pi). * all concurrent medications taken for any reason stable for 14 days * ability to follow protocol with reference to cognitive and situational factors (e.g. stable housing, ability to attend visits) * ability to read and write english * willing and able to give informed consent exclusion criteria: * currently using other topical agents for treatment of pain or inflammation * use of glucosamine, methysulfonylmethane or other regular anti-inflammatories within 2 weeks prior to completing baseline pain measure and during the trial * presence of significant medical disorder that would compromise the participant's safety to take part in the trial (e.g. cancer, immunosuppressed) * pregnant and breastfeeding women. * type i or type ii diabetes and other endocrine disorders * use of exercise or transcutaneous electrical nerve stimulation prior to and during the trial * a history or present disease (i.e. inflammatory, infectious joint disease) which may affect the outcome of the trial * currently taking nhps for joint health * currently enrolled in other clinical trial involving a pharmaceutical treatment
the association between anemia and cardiomegaly

Conditions: Anemia in Children; Cardiomegaly

Summary: anemia is one of the major global problems that continues to this day. according to world health organization (who) data, anemia is found in 1.62 billion people or equivalent to 24.8% of the world's population while, the prevalence of anemia in children under 6 years of age in indonesia reached 38.4%. anemia, if undiagnosed or untreated for a long period of time can lead to multiorgan failure. the cardiovascular system is the most commonly affected system in chronic anemia. between one-third and two-thirds of patients with severe anemia have cardiomegaly and this will return to normal within a few weeks after the anemia is well managed. this abnormality can be evaluated on chest radiograph or echocardiography.


Eligibility criteria:
inclusion criteria: * anemia patients aging maximum 18 years old * anemia patients who had undergone chest radiograph and echocardiography exclusion criteria: * anemia patients who had undergone definitive surgery * anemia patients who had took iron supplementation in the last 3 months * anemia patients who had other anemic conditions such as chronic kidney disease or hemolytic anemia
brain markers of depression vulnerability: the case of prefrontal haemodynamic response

Conditions: Depression

Summary: functional near infrared spectroscopy (fnirs) offers a cheap and reliable tool to investigate prefrontal brain activation in the healthy and diseased human brain. as such, fnirs bears great potential as a diagnostic tool for clinical practice. research indicates that fnirs, together with a relatively simple task to activate the prefrontal cortex, the so-called verbal fluency task (vft), elucidates prefrontal dysfunction in major depressive disorder (mdd). this finding can potentially serve as an imaging marker for disease pathology, even when depressive symptoms are absent. indeed, recent research also suggests prefrontal dysfunction in fully remitted mdd (rmdd). prefrontal haemodynamic responses may therefore serve as a trait marker for mdd vulnerability. this study aims to investigate the haemodynamic response in rmdd, healthy participants with increased mdd risk (hcr; having a 1st-degree relative with mdd), and low-risk healthy participants (hcnr; having no 1st-degree relatives with mdd) using fnirs. the investigators hypothesize lower prefrontal reactivity in hcr compared to hcnr, and lowest prefrontal reactivity in rmdd compared to hcnr. this study has the potential to elucidate the neuronal underpinnings of depression vulnerability in the absence of symptoms that are sometimes considered a confounding factor when it comes to studying the biological encoding of depression.

healthy participants with a high risk of mdd (hcr), healthy participants with a low risk of mdd (hcnr) and rmdd participants will be included in this study. prefrontal haemodynamic response will be measured in all participants during the verbal fluency test (vft) using 52 channels fnirs. the vft involves two neural conditions, one positive condition, and one negative condition. both the neuroimage change and the behavioral outcomes of vft will be compared within-group and among groups. the correlation between the neuroimage change and the behavioral outcomes will be analyzed as well.

Eligibility criteria:
inclusion criteria: * mini-mental state examination (mmse) \> 24 exclusion criteria: * current diagnosis of psychiatric disorders, such as depression, anxiety, schizophrenia, or autism * current or past diagnosis of neurological disorders, such as head injuries, strokes, encephalitis, epilepsy, parkinson's, or alzheimer's

Keywords: remitted major depression depression vulnerability
tiptraq home sleep test validation study, duke

Conditions: Obstructive Sleep Apnea

Summary: a validation study has been designed to assess the performance of a home sleep test device, tiptraq, for screening sleep apnea. the study involves participants wearing the tiptraq device on their fingertip during a traditional sleep test, known as polysomnography (psg), conducted in a sleep center. the performance of the device will then be evaluated by comparing the results from the tiptraq system with those from the traditional sleep test.

this clinical study is designed to validate tiptraq, a new sleep screening device developed by pranaq, for the detection of sleep breathing disorders (sbd), including obstructive sleep apnea-hypopnea syndrome (osahs). given the high prevalence of undiagnosed osahs and the cumbersome nature of traditional polysomnography (psg) - which involves multiple sensors and specialist interpretation - there is a pressing need for more accessible screening tools. tiptraq aims to meet this need through a wearable device that utilizes photoplethysmography (ppg) and an accelerometer to monitor essential physiological parameters during sleep. this information is then analyzed by an interpretable artificial intelligence (ai) system to estimate key indicators of sleep health such as spo2, total sleep time (tst), oxygen desaturation index (odi), and apnea-hypopnea index (ahi). the study is open-label and non-randomized, planning to recruit 125 subjects. participants will use the tiptraq device alongside a companion mobile app, with data analysis supported by ai technology hosted on a cloud server. the primary goal is to assess the accuracy of the tiptraq system by comparing its output against the gold standard psg annotations made by sleep experts. this initiative represents a significant step towards simplifying and democratizing the screening process for sleep disorders, potentially enabling early detection and treatment for a larger segment of the population, thus mitigating personal health risks and broader societal impacts of undiagnosed sbd.

Eligibility criteria:
inclusion criteria: subjects from the age of 20 and older that have an indication for an in-lab psg study in the duke university hospital. the subject should be able to understand the study and sign the informed consent before being enrolled in the study. during the study period, the subject can withdraw from the study anytime. exclusion criteria: subjects with the following medical conditions will be excluded from this study: 1. heart transplant 2. heart failure, new youk heart association (nyha) classification iii or iv 3. chronic obstructive lung disease, global initiative for chronic obstructive lung disease (gold) categorization 3 or 4 4. chronic opioid medication user devastating severe strokes, with the modified rankin score (mrs)≥4 5. tracheostomy 6. incapable of comprehending and signing the informed consent and questionnaires, including but not limited to subjects with severe alzheimer's, unconscious by head trauma, or of someone with limited mental capacity 7. cannot correctly follow the order to use the tiptraq device

Keywords: obstructive sleep apnea
efficacy and acceptability of two lubricant eye drops

Conditions: Dry Eye Syndromes

Summary: efficacy and acceptability of two new artificial tears following two weeks of treatment in patients with dry eye. patients will be randomized to 1 of 2 treatments for 7 days then crossover to the alternate treatment for 7 days.


Eligibility criteria:
inclusion criteria: * male or female * at least 18 years of age * current use of artificial tears exclusion criteria: * any uncontrolled systemic disease * pregnancy or planning a pregnancy * contact lens wear
mirnas in periodontal disease

Conditions: Periodontal Diseases; Periodontitis; Gingivitis

Summary: it has been stated that microrna (mirna) play an important role in development, homeostasis and immune functions, and abnormal mirna expression may cause faster disease progression. the aim of this study was to determine mir-203, mir-142-3p, mir-146a, mir-146b, mir-155, mir-29b gene expressions in saliva of the patients with periodontal disease before and after non-surgical periodontal therapy (nspt) and to evaluate the effect of smoking on these mirnas. a total of 90 individuals, 30 with periodontitis, 30 with gingivitis, and 30 periodontally healthy (control group), were included. these three groups were divided into subgroups as smoking and non-smoking individuals, with 15 people in each group. nspt was applied to patients with periodontitis and gingivitis. saliva samples and clinical parameters were taken from at baseline and repeated 6 weeks after nspt.


Eligibility criteria:
inclusion criteria: have at least 20 natural teeth, excluding third molars. periodontitis patients had at least two non-adjacent sites per quadrant with probing depth (pd) ≥ 5 mm and clinical attachment level (cal) ≥ 5 mm with gingival inflammation, and alveolar bone loss affecting \>30% of the teeth, as detected on clinical and radiographical examinations. gingivitis patients had without attachment and alveolar bone loss who had gingival inflammation, pd ≤ 3 mm and bop \> 30% in the entire mouth periodontally healthy control group had no sign of gingival inflammation, no pd \> 3mm and no evidence of attachment or bone loss exclusion criteria: history of systemic disease. regular use of any drugs which can effect the immune system or inflammatory response in the 6 months preceding the start of the study. periodontal treatment during last 6 months that could affect periodontal status. history of radiotherapy or chemotherapy. current pregnancy, lactation or menopause.
qualitative research on women with congenital adrenal hyperplasia

Conditions: Congenital Adrenal Hyperplasia

Summary: this qualitative interview-based study will investigate the impact that living with congenital adrenal hyperplasia has for women in the following areas: health-related quality of life (hrql), psychological health, and health-seeking behaviors.

congenital adrenal hyperplasia is a chronic-illness requiring life-long treatment and is caused by an inherited enzyme deficiency that leads to an overproduction of hormones produced by the adrenal glands, which in turn, masculinizes the female genitalia before birth. while the mechanisms by which cah influences physiological development are understood, the impact of this hormonal elevation on health-related quality of life (hrql), psychological health, and health-seeking behaviors is less clear. this study is guided by three research questions: (1) how does cah influence hrql domains (physical, functional, emotional and interpersonally), (2) how does cah influence the mental health of women diagnosed with cah, and (3) how does cah influence decisions to seek help from a counselor? semi-structured qualitative interviews will be conducted with women with cah. interviews will be analyzed through the consensual qualitative research (cqr) methodology.

Eligibility criteria:
inclusion criteria: * 46xx, females * diagnosed by a physician with cah (either simple-virilizing or salt-losing types) * willing to complete a brief demographic questionnaire and participate in an hour long telephone interview exclusion criteria: * non-classical or late-onset cah

Keywords: adrenal hyperplasia, congenital psychosexual development sexual development intersex qualitative cah interview disorder of sex development telephone quality of life mental health counseling
therapeutic plasma exchange adsorption diafiltration

Conditions: Septic Shock; Multiple Organ Dysfunction Syndrome

Summary: the purpose of this study is to evaluate the efficacy of coupled therapeutic plasma exchange adsorption diafiltration (peaf )for treating septic shock with multiple organ dysfunction syndrome patients in icu.

septic shock with multiple organ dysfunction syndrome (mods) is a life-threatening clinical condition due to coagulant disorder immunoparalysis to infection. for this reason the extracorporeal therapies for the treatment of septic shock with mods have become widespread in the icu and, at the same time, new extracorporeal depurative techniques have been developed for the removal of inflammatory mediators. one of these techniques is therapeutic plasma exchange (tpe) that remove pathologically elevated cytokines and simultaneously to replace protective plasmatic factors. other techniques is coupled plasma-filtration adsorption (cpfa) that uses a sorbent once the separation between plasma and blood has been obtained with a plasma filter. the others is plasma dialysis filtration(pdf) that can remove inflammatory mediators for patients with multiple organ dysfunction syndrome.the purpose of this study is to evaluate the efficacy of peaf (coupled therapeutic plasma exchange adsorption diafiltration )for treating septic shock with multiple organ dysfunction syndrome patients in icu.

Eligibility criteria:
inclusion criteria: 1. age, gender: 18-75 years old, male or female; 2. basic conditions: 20 ≤ apache ii score ≤ 35 points and 10 ≤ sequential organ failure assessment(sofa)≤ 18 points; 3. septic shock : on the basis of sepsis, after adequate fluid resuscitation, sustained hypotension requires maintenance of vasoactive drugs, mean arterial pressure（map）≥ 60 mmhg and lactate ≥ 2.0 mmol/l; mods: if the patient's sofa score is ≥2 points, it means there is organ dysfunction. when the patient has two or more organ dysfunctions, it is mods. exclusion criteria: 1. can not remove the cause (surgical patients refused surgery, pan drug resistant infection without drug use) 2. allergic to amplya™ series 3. presence of relative or absolute contraindications to pfa 4. mods caused by severe liver disease 5. malignant tumors 6. chronic end-stage disease (predicted to survive no more than one month) 7. maternal and possibly pregnant women 8. participated in drug clinical trials within three months 9. admission from an other icu where the patient remained for more than 24 hours
a randomized multicenter study of daylight mediated photodynamic therapy (pdt)

Conditions: Actinic Keratoses

Summary: a randomised, multi-center study of daylight mediated photodynamic therapy (pdt) with metvix in patients with multiple actinic keratosis on the face and/or scalp.


Eligibility criteria:
inclusion criteria: * 18 years and older, 5 ak in face and scalp exclusion criteria: * immunosuppression
a study to evaluate the effect of aleglitazar on cardiac energetics and function in patients with type 2 diabetes mellitus and no history of coronary artery disease

Conditions: Diabetes Mellitus Type 2

Summary: a single center, double-blind, placebo-controlled, randomized, crossover, phase ii study to assess the effect of aleglitazar on cardiac energetics and function in patients with uncomplicated type 2 diabetes mellitus and no history of coronary artery disease who are drug-naïve or treated with stable metformin. eligible patients will receive either 150 mcg aleglitazar or placebo orally daily for 6 weeks. after a washout period of 6 weeks, patients will cross over to the treatment not yet received.


Eligibility criteria:
inclusion criteria: * adult patients, 40 to 70 years of age (inclusive) at screening * patients with type 2 diabetes mellitus diagnosed at least 12 weeks before screening and either drug-naïve or treated with stable metformin monotherapy for at least 12 weeks prior to screening * hba1c \>/= 7 % and \</= 9% at screening * absence of history of coronary artery disease exclusion criteria: * diagnosis or history of type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary forms of diabetes * current treatment with fibrates, thiazolidinediones, or insulin * prior intolerance to thiazolidinediones and/or fibrates * clinically significant liver disease or impaired liver function * know chronic diabetic complications (i.e. retinopathy, neuropathy, nephropathy) * symptomatic congestive heart failure classified as nyha class ii-iv * diagnosed and/or treated malignancy within the past 5 years, except for treated basal cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer * contraindications to mri, or inability to tolerate mri scanning
pterygopalatine fossa block in aneurysmal subarachnoid hemorrhage

Conditions: Subarachnoid Hemorrhage, Aneurysmal

Summary: aneurysmal subarachnoid hemorrhage (asah) can cause a severe headache (ha) that is famously treatment-resistant. current pain regimens are too reliant on opioids, which results in long-term opioid dependence and can obfuscate the neurological examination, which is critical to detect vasospasm and delayed cerebral ischemia. this study will gather the initial evidence of whether the pterygopalatine fossa (ppf) regional anesthesia nerve block can treat asah-related ha and reduce opioid consumption in patients with asah.


Eligibility criteria:
inclusion criteria: * aneurysmal subarachnoid hemorrhage with secured aneurysm * age greater than or equal to 18 years * able to communicate pain level exclusion criteria: * documented allergy to local anesthetics (e.g. bupivicaine) * patients with unsecured aneurysms * patients who are unable to communicate pain level (e.g. sedation/mechanical ventilation/delirium, etc) * medical treatment for vasospasm including blood pressure/inotropic augmentation * angiographic treatment for vasospasm within 48 hours
urokinase versus video-assisted thoracoscopic to treat complicated parapneumonic empyema in childhood

Conditions: Empyema; Pneumonia

Summary: a great controversy exists about which is the best method to perform the evacuation of the collection. the purpose of this study is to evaluate which is the best initial treatment to drain complicated parapneumonic empyema (stages ii and iii) in children: the present study raises a hypothesis of equivalence between both arms of treatment (chest drainage plus intrapleural urokinase or videothoracoscopic debridement).


Eligibility criteria:
inclusion criteria: * patients less than 15 years of age with pneumonia and persistent fever, and complicated parapneumonic empyema (septation or loculation seen on ultrasound or rx thorax)stages ii and iii requiring an intervention to drain exclusion criteria: * existing contraindications or other previous conditions, hypertension, pneumothorax

Keywords: empyema urokinase thoracoscopic childhood
wearable device to increase physical activity amongst adults with pain

Conditions: Musculoskeletal Chronic Pain Conditions

Summary: this protocol is for a pragmatic mixed methods randomized parallel-group exploratory feasibility trial to examine all facets of a proposed future phase iii trial on the use of wearable device to increase physical activity and possibly reduce pain amongst middle-aged people with musculoskeletal (msk) chronic pain. the feasibility study is intended to answer the following research questions: question 1 evaluate the acceptability of all aspect of the study design of wearable devices as an intervention to increase physical activity in middle-aged adults with musculoskeletal chronic pain. question 2: is it feasible and acceptable to use wearable devices as an intervention to increase physical activity in middle-aged adults with musculoskeletal chronic pain? question 3: how can using wearable device promote physical activity effectively in middle-aged adults with musculoskeletal chronic pain? participants will be recruited from a national health service (nhs) pain clinic and randomised on a ratio1:3 into control group (standard care) and intervention group (standard care combined with wearable device). the feasibility study will last for 18 months, participants involvement will be for 24 weeks. patients in both groups can participate in any physical activity, including planned, structured, and repetitive bodily movement exercise or occupational and recreational pa. qualitative semi-structured interview will be conducted at baseline and week-12, while outcome measures will be conducted at baseline, 4-week, 8-week,12-week, and 24-week for all participants to examine their pain, physical activity, and their responses to the trial. qualitative interview will be conducted for stakeholders which include clinicians and service managers after all patient data has been collected. this study has the potential to make an original contribution to provide key data on the feasibility, acceptability, and effectiveness of using wearable technology to support physical activity intervention for middle-aged adults with musculoskeletal chromic pain.


Eligibility criteria:
inclusion criteria: * patient of any gender identity 40-65 years old. * willingness to participate in the trial. * able to understand and speak sufficient english to engage during interviews. * they have self-reported persistent or recurrent musculoskeletal pain for three months or longer. * participants will be receiving treatment for musculoskeletal chronic pain. exclusion criteria: * palliative patient. * patients of any gender identity younger than 40-year-old or older than 65-year-old. * patients that are dependent on alcohol or drugs. * involvement with other ongoing studies. * patients unable to complete the questionnaires as judged by the researcher.
safety education in the emergency department: a pilot study

Conditions: Firearm Injury

Summary: the purpose of this pilot study is to assess the feasibility and acceptability of video-based safe firearm storage education in the pediatric emergency department.


Eligibility criteria:
inclusion criteria: * children \> 30 days and \< 18 years old presenting to the chco ed * parent/guardian who is ≥ 18 and ≤ 85 years old * arms 1 \& 2 will include a subset of patients ≥10 years and \< 18 years old with a firearm in the home. exclusion criteria: * child is in an emergent/acute medical condition * patient seen in our fast track area or other room without a television * parent/guardian is non-english speaking.

Keywords: injury prevention anticipatory guidance firearm counseling